Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
ADXS

ADXS - Advaxis Inc Stock Price, Fair Value and News

$0.48-0.03 (-5.88%)
Market Closed

1/100

ADXS

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

1/100

ADXS

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

$0.37

Target 3M

$0.41

Target 6M

$0.39

ADXS Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

ADXS Price Action

Last 7 days

10.9%

Last 30 days

1175%

Last 90 days

920.0%

Trailing 12 Months

1600%

ADXS RSI Chart

ADXS Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

ADXS Valuation

Market Cap

21.7M

Price/Earnings (Trailing)

-0.45

Price/Sales (Trailing)

1.7K

EV/EBITDA

-0.48

Price/Free Cashflow

-0.74

ADXS Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

$0.37

Target 3M

$0.41

Target 6M

$0.39

ADXS Fundamentals

ADXS Revenue

ADXS Earnings

ADXS Profitability

Free Cashflow Yield

-135.86%

ADXS Investor Care

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
2023522.3K352.5K182.8K13.0K
20222.1M958.0K580.7K250.0K
20211.2M2.2M3.2M3.2M
2020014.0M7.1M253.0K
201923.7M23.1M22.0M20.9M
201810.3M8.6M6.7M6.1M
20177.5M11.0M14.0M12.0M
20161.3M250.0K250.0K4.0M
20140672.3K836.2K1.0M
201000269.1K508.5K
200900029.7K
Get all data in R, Python etc through our Historical Stock Data APIs

About Advaxis Inc

ADXS
Ayala Pharmaceuticals, Inc., a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. It is also developing proprietary Lm-based antigen delivery products for patients suffering from common cancers. The company's lead candidates under development are AL102, which targets the aberrant activation of the Notch pathway with gamma secretase inhibitors to treat various tumors, including desmoid tumors; and ADXS-504, a Lm-based therapy for early-stage prostate cancer. Ayala Pharmaceuticals, Inc. was founded in 2017 and is based in Monmouth Junction, New Jersey.
0
 CEO
 WEBSITEayalapharma.com
 SECTORHealthcare
 INDUSTRYBiotechnology

Advaxis Inc Frequently Asked Questions

ADXS is the stock ticker symbol of Advaxis Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Tue Jan 27 2026, market cap of Advaxis Inc is 21.74 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check ADXS's fair value in chart for subscribers.

The fair value guage provides a quick view whether ADXS is over valued or under valued. Whether Advaxis Inc is cheap or expensive depends on the assumptions which impact Advaxis Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ADXS.

As of Tue Jan 27 2026, ADXS's PE ratio (Price to Earnings) is -0.45 and Price to Sales (PS) ratio is 1.67 Thousand. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ADXS PE ratio will change depending on the future growth rate expectations of investors.